ASA Direct Remittance Ad
UK broadcast financial ads must not solicit direct payments or investments from the spot without first directing the audience to product information.
UK broadcast financial ads must not solicit direct payments or investments from the spot without first directing the audience to product information.
Under CSA Staff Notice 21-330, crypto marketing in Canada must give balanced, prominent risk information and must not describe crypto assets as safe or guaranteed.
Arizona insurance administrators may use advertising about an insurer's business only with the insurer's prior written approval, and must not misstate the insurer's role.
Swiss real estate fund marketing must be identifiable as advertising, refer to the prospectus and KID, present performance fairly with a past-performance caveat, disclose key risks and substantiate sustainability claims.
ASIC expects risk warnings and qualifiers in financial ads to be clear and prominent enough to correct the impression created by headline claims; hidden or unreadable qualifiers can make an ad misleading.
Australian financial product ads must give balanced information, including the key conditions, fees and risks that bear on highlighted benefits, regardless of the medium's size limits.
ASIC applies the same advertising standards to online, social, influencer and in-app financial promotions as to traditional media; short formats must still carry balancing risk information, issuer and PDS statements and paid-relationship disclosure.
Prop 65 requires clear and reasonable warnings, visible before purchase including online, for California exposures to listed chemicals; safe-harbor warnings must include the signal word, a named chemical, the endpoint and the P65Warnings URL.
Prop 65 requires clear and reasonable warnings before California exposure to listed chemicals; dietary supplements use the food-warning safe harbor, warnings must name a chemical, and online sales must show the warning before purchase.
Canadian crypto-asset ads must give balanced risk information and must not guarantee or predict returns, imply CDIC coverage or suggest regulatory endorsement.
Canadian fund ads must not describe a fund's risk in a way that conflicts with its Fund Facts or ETF Facts risk rating or imply guarantees that do not exist.
Bars non-bank fintech and BaaS marketing from misrepresenting FDIC insurance and requires it to say it is not a bank, name the insured bank and explain coverage limits.
Requires Delaware long-term care ads to avoid absolute coverage and premium claims, note benefit triggers and elimination periods when benefits are described, and disclose agent contact on lead-generating materials.
MiFID retail marketing must name the investment firm and present risks fairly and prominently, with risk warnings at least as large as the predominant font.
MiFID marketing showing future performance must use reasonable assumptions and positive and negative scenarios, disclose charge effects if gross, avoid simulated past performance and warn prominently that forecasts are not reliable.
Under IDD Art. 17(2), insurance marketing in the EU must be fair, clear and not misleading and clearly identifiable as marketing.
EU banking product ads must not describe products as safe, guaranteed or risk-free without stating the conditions and limits that apply.
Marketing for EU insurance-based investment products must present returns, guarantees, risks and costs fairly and not misleadingly.
EU fund marketing that mentions potential returns or benefits must describe the risks with equal prominence.
UK insurance marketing must communicate cover, price, exclusions and comparisons in a clear, fair and not misleading way.
UK promotions of restricted mass market investments such as P2P must carry the prescribed, prominent risk warning and must not offer incentives to invest.
21 CFR Part 201 requires OTC drug labels to carry a standardized Drug Facts panel and prescription labels to carry 'Rx only', with label claims consistent with approved labeling.
Requires consumer TV, radio and video prescription drug ads to present the major statement of risks clearly, conspicuously and neutrally and to provide a brief summary or adequate provision.
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.
Requires prescription drug advertising in all channels to present risks with fair balance, include a brief summary or equivalent, and avoid overstated, off-label or unsupported claims.
Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.
Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.
Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.
Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.
Canadian consumer credit ads and disclosures must state key cost and payment terms in clear, simple language.
Broker-dealer promotion of leveraged/inverse ETFs, volatility products, structured notes and margin must prominently explain the product's specific risks and not downplay complexity.
Bond fund volatility ratings in retail communications must name the rating entity, be current to the latest quarter end, explain the rating, note there is no standard method and point to the methodology.
Health product ads must give an overall impression that matches what the evidence supports, with any needed qualifications clear, conspicuous and placed next to the claim in the same medium.
Homeopathic ad disclosures must be clear, conspicuous and close to the claim, and visuals or endorsements must not imply scientific or medical validation that contradicts them.
Under FTC Act Section 5, qualifying disclosures must be clear, conspicuous and near the claim, and fine print cannot contradict the headline's net impression.
Used car dealers must post a Buyers Guide on each vehicle and must not make ad or sales statements that contradict its 'As Is' or warranty disclosures.
Kentucky life, health and annuity marketing may not cite the guaranty association or imply state-backed protection as a selling point.
LinkedIn ads must show a display URL that matches the destination domain and must lead to a landing page without blocking pop-ups or interstitials.
Maryland long-term care insurance ads may not misstate premium stability, make unfair comparisons, describe benefits without noting limitations, or use false urgency.
Massachusetts insured health plan marketing must identify the carrier and, when it states costs, coverage or network claims, include the material conditions and exclusions and avoid unsubstantiated endorsements.
Meta OTC drug ads must make claims consistent with the product's Drug Facts uses and warnings, without cure, guaranteed-speed or unsupported prescription-strength claims; no set ad wording is required.
Municipal bond ads must be fair, balanced and not misleading, state yields with their basis, and qualify tax-free claims.
Annuity ads must not falsely claim no commission, no conflicts, independence, fiduciary status or guaranteed best interest.
A credit union must not misrepresent NCUA share insurance in its ads, such as by extending it to investments or loans, implying unlimited coverage or naming the wrong insurer.
New York Regulation 34-A requires life insurance and annuity ads to be truthful, identify the insurer, accurately present guaranteed and non-guaranteed elements and disclose material limitations.
Bank marketing for crypto custody and stablecoins must not describe crypto as FDIC-insured or bank-guaranteed, describe stablecoins as legal tender or government-backed, or imply OCC approval.
Bank marketing must not present nondeposit investment products as sold at the teller line or as part of deposit-taking; sales should be shown as separate from deposit activity.
DTC TV and radio prescription drug ads must present the major risk statement in consumer-friendly language, at comparable audio quality, with concurrent on-screen text on TV and without distracting elements.
Quebec investment promotions must not call investments safe or risk-free without basis and must give balanced, visible risk statements near performance claims.
Marketing for registered variable annuities and variable life must not imply investment values are guaranteed or risk-free and must balance performance with risk of loss.
Marketing for fixed indemnity, short-term and other limited-benefit health plans must not present them as comprehensive or major medical coverage.
Replacement and 1035-exchange ads must not misrepresent existing or new policies or present switching as cost- or risk-free.
Tennessee Medigap ads must not imply government or Medicare affiliation and must identify the insurer and describe benefits plainly.
Texas Medicare supplement ads must not imply government endorsement, call premium-bearing coverage free, or misstate benefits or renewability.
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
UK critical illness cover marketing must not promise payouts for headline conditions without signalling that cover depends on policy definitions and severity.
UK income protection ads must not present benefit levels or triggers in a way that omits material qualifiers such as deferred periods, caps or the incapacity definition.
UK pet insurance ads must be clear, fair and not misleading about the type of cover and its key limits, such as pre-existing condition exclusions, age limits and excess.
Vermont health insurance ads must not mislead about benefits, exclusions, limitations or acceptance, and invitations to contract must note exceptions and limitations and identify the insurer.